Ranbaxy Laboratories has received the final approval from the US Food
and Drug Administration’s (USFDA) to sell Ramipril capsules (in 5mg
& 10mg), a drug used to treat cardiovascular diseases. The
application for the drug was submitted by Ranbaxy from Ohm Laboratories
(New Jersey), USA, its subsidiary. “The office of generic drugs, USFDA,
had determined the Ranbaxy formulations to be bioequivalent and having
the same therapeutic effect as the original drug, Altace, made by King
Pharmaceuticals Inc, “a Ranbaxy release said. This is the third
marketing approval from Ohm Laboratories in the last two months.
Ramipril is the generic version of Altace.
As Indians we know India in itself is an amazing nation and even the world agrees with that, however, grass is always greener on the other side and that is why Indians desire to immigrate a More
Helplinelaw can set up your session with quality and experienced lawyers to discuss and resolve your legal matters. You can avail consultation in form of sending questions, phone call or webchat discussion More